Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Something about this statement says BUY!!!
"“Following our recent announcement regarding a successful FDA meeting for our immediate release Oxycodone HCl product SequestOx™, I am now very pleased to announce these positive topline study results for an abuse-deterrent twice-daily Oxycodone,” said Nasrat Hakim, President and CEO of Elite Pharmaceuticals. “We intend to file an ANDA for this product later this year.”
Quote:
"That's not what the RS will be used for, it will used to wipe out current shareholders and give nasRAT about another 950 million shares to sell."
Says John-Langston, a username on a free website....
Come on John, I don't mean to fire shots but of course the CEO is gonna have faith in his company...
I'm already in friend, 100k shares @.145 average.... not the whole basket but I'm capped for now, I have to either cash out other investments or wait til payday.... cashing out other plays is against my rules so I have to wait til payday
Hahaha, that's how I started trading 15 years ago.... went to the casino, hit a jackpot and haven't stopped yet, only difference is here is the wait ... maybe I'll go tonight. Good luck to you.
Well if anything was a sure thing there would be no profit in securities trading or market volatility , our economy would crumble and our country would be devastated....so yes SPECULATION, which goes both ways, if my speculation based on due diligence is accurate I won't have a mortgage anymore, and if your speculation is accurate then I guess I'll have to wait to retire...
LOL.... I'm actually hoping we don't hear anything til the 30th.... I can't load up until next friday....damn mortgage payments keep getting in the way...
Speculation my friend, as you speculate based on your beliefs others speculate to the contrary....based on all the information available I'm more than confident that I will turn a significant profit here, everyone invests the way that suits them, win some lose some, this is going in the WIN column. If you believe otherwise, more power to you.
Share price last week, this week, next week is irrelevant....balance sheets is where it is AFTER sequestox and more generics APPROVAL... if you plan on being here LONG, you will make buckets of cash, if just for the short term, cash out after next PR/CC explaining how we will be approved, you'll still make a decent profit...
Quote from same article:
"We are extremely pleased that there is a path forward to seek FDA APPROVAL of SequestOx™," said Nasrat Hakim, President and CEO of Elite. "Based on the guidance received from the agency, Elite will begin to execute the proposed plan immediately."
So NOWHERE is the wrong word to use
Nope, no problems, none at all, buy some shares, you'll make money, I already have .
Don't forget all the free media coverage they will receive being the first approved drug of its kind with that labeling....
They agreement was established 16 years ago, it was converted for $360k+ ....not $7million in 2016....the total shareholder liability is only $377k..... from the same report you are citing, I can copy and paste stuff from the same report that makes the stock look like it's worth $3.50..... either post everything or don't post at all
Here's where you got your DD from......
https://www.otciq.com/otciq/ajax/showFinancialReportById.pdf?id=158905
5,000,000,000
Authorized shares
Here's where the shares went
That was 16 years ago
I think it will be a combined communication, if it's very very good news he will release a PR then have the CC, I expect a moderate share price improvement leading up to the info, then after the CC, a significant jump
On watch definitely, ask is at $200k haha, wonder what it will open at
We'll have to wait and see what develops in the next CC/PR.... either way, Elite has proven they can conduct both if necessary, they did it with generic oxy as we have seen...
My opinion is similar to yours, which I believe is as follows: $$$$$$
Quote:
"The product’s approval is supported by a clinical program that evaluated the safety and efficacy of VANTRELA ER, as well as its abuse potential in laboratory-based in vitro manipulation and extraction studies, pharmacokinetic studies, and clinical abuse potential (CAP) studies."
Looks like they were able to get approval using in vitro studies... not necessarily requiring a human trial..... hmmmm, someone was convinced of the contrary...
Nice find lasers
Quote:
"The product’s approval is supported by a clinical program that evaluated the safety and efficacy of VANTRELA ER, as well as its abuse potential in laboratory-based in vitro manipulation and extraction studies, pharmacokinetic studies, and clinical abuse potential (CAP) studies."
Looks like they were able to get approval using in vitro studies... not necessarily requiring a human trial..... hmmmm, someone else on this board was convinced of the contrary...
I don't see it.... but one thing is for sure, we have a higher price foundation this month and hopefully we can bust through that .18 resistance before news comes out
Touché , elite will prevail
They don't have too, Perdue can't stop elite
Show me proof, like I showed you, I would appreciate the help in saving my portfolio, be a pal
Generic abuse deterrent OxyContin is going to get approved, Perdue can't do a damn thing about it.
http://www.fiercepharma.com/sales-and-marketing/purdue-loses-a-battle-war-against-oxycontin-generics
It's bad news for Purdue Pharma but good news for generics makers such as Teva Pharmaceutical Industries ($TEVA). A federal appeals court affirmed a lower court's decision to toss out some Purdue patents for its top-selling pain drug OxyContin, further opening the door to cheap knockoff versions of the blockbuster med.
AND THIS:
"What one might gather from the Board’s memorandum is that the scope of the period of 3-year exclusivity for OXYCONTIN expiring on April 16, 2016 applies to the particular drug product formulation studied in clinical trials, and not broadly to prevent approval of all oxycodone extended-release drug products with abuse-deterrence labeling. That would seem to be consistent with other FDA decisions. For example, on January 4, 1999, FDA approved ANDA 075102 for Propofol Injectable Emulsion, 1% (10 mg/mL), notwithstanding a period of 3-year exclusivity on the reference listed drug, DIPRIVAN, that was not scheduled to expire until June 11, 1999. The period of 3-year exclusivity applicable to DIPRIVAN was based on FDA’s approval of a NDA Supplement for a version of the drug product formulated with EDTA as a preservative. FDA determined that the ANDA sponsor, whose drug product was formulated with sodium metabisulfite as the preservative in place of EDTA, was not subject to the exclusivity applicable to the EDTA-formulated version of DIPRIVAN because the scope of 3-year exclusivity was limited to the drug product formulation."
Funny how people assume we don't know how to use google...
Generic abuse deterrent OxyContin is going to get approved, Perdue can't do a damn thing about it.
http://www.fiercepharma.com/sales-and-marketing/purdue-loses-a-battle-war-against-oxycontin-generics
It's bad news for Purdue Pharma but good news for generics makers such as Teva Pharmaceutical Industries ($TEVA). A federal appeals court affirmed a lower court's decision to toss out some Purdue patents for its top-selling pain drug OxyContin, further opening the door to cheap knockoff versions of the blockbuster med.
AND THIS:
"What one might gather from the Board’s memorandum is that the scope of the period of 3-year exclusivity for OXYCONTIN expiring on April 16, 2016 applies to the particular drug product formulation studied in clinical trials, and not broadly to prevent approval of all oxycodone extended-release drug products with abuse-deterrence labeling. That would seem to be consistent with other FDA decisions. For example, on January 4, 1999, FDA approved ANDA 075102 for Propofol Injectable Emulsion, 1% (10 mg/mL), notwithstanding a period of 3-year exclusivity on the reference listed drug, DIPRIVAN, that was not scheduled to expire until June 11, 1999. The period of 3-year exclusivity applicable to DIPRIVAN was based on FDA’s approval of a NDA Supplement for a version of the drug product formulated with EDTA as a preservative. FDA determined that the ANDA sponsor, whose drug product was formulated with sodium metabisulfite as the preservative in place of EDTA, was not subject to the exclusivity applicable to the EDTA-formulated version of DIPRIVAN because the scope of 3-year exclusivity was limited to the drug product formulation."
http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2015/08/a-look-at-fdas-rationale-for-granting-and-the-scope-of-exclusivity-for-abuse-deterrent-oxycontin.html
I don't think so
"What one might gather from the Board’s memorandum is that the scope of the period of 3-year exclusivity for OXYCONTIN expiring on April 16, 2016 applies to the particular drug product formulation studied in clinical trials, and not broadly to prevent approval of all oxycodone extended-release drug products with abuse-deterrence labeling. That would seem to be consistent with other FDA decisions. For example, on January 4, 1999, FDA approved ANDA 075102 for Propofol Injectable Emulsion, 1% (10 mg/mL), notwithstanding a period of 3-year exclusivity on the reference listed drug, DIPRIVAN, that was not scheduled to expire until June 11, 1999. The period of 3-year exclusivity applicable to DIPRIVAN was based on FDA’s approval of a NDA Supplement for a version of the drug product formulated with EDTA as a preservative. FDA determined that the ANDA sponsor, whose drug product was formulated with sodium metabisulfite as the preservative in place of EDTA, was not subject to the exclusivity applicable to the EDTA-formulated version of DIPRIVAN because the scope of 3-year exclusivity was limited to the drug product formulation."
http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2015/08/a-look-at-fdas-rationale-for-granting-and-the-scope-of-exclusivity-for-abuse-deterrent-oxycontin.html
Did you guys really think that those people who bought at .0001 and ..0002 weren't going to take some profit? Not everybody who trades on these levels is looking to make 1000%, some people are happy with just doubling or tripling their money.... you can't do that with blue chips, everybody calm down and see what pans out .... all we need is a PR and you'll get your 1000%
Again, re-establishing a better base here via consolidation and higher share price, 1.5 million trades at these levels.... a good PR about sequestox and we're golden.....
Fluff PR? All they did was report positive Top Line results, as any pharma company would do.... they are required to by law.... this is standard operating procedure.
All we need is a PR
Only 10 mil left...
SMAA---
MMs are buying at the ASK..... they want more shares!!!!
MMs are buying at the ASK..... they want more shares!!!!
We are definitely heading there my friend....
We're so focused on sequestox.... this is huge too, we should have seen it coming though, he did say a new he will file for a new drug every quarter for the next 4 quarters, this a a big deal, a piece of a $2.5 billion market.... everyone always takes the generic, it's more affordable....at least I do when I fill my prescriptions.
We also know now how long a fasting/fed study takes as well, couple of months tops....
If there is a new study requiring a fed participant I'm volunteering, only because the meal the FDA recommends is as follows:
"An example test meal would be two eggs fried in butter, two strips of bacon, two slices of toast with butter, four ounces of hash brown potatoes and eight ounces of whole milk. Substitutions in this test meal can be made as long as the meal provides a similar amount of calories from protein, carbohydrate, and fat and has comparable meal volume and viscosity."